Results 51 to 60 of about 22,759 (276)

Bispecific antibodies for viral immunotherapy

open access: yesHuman Vaccines & Immunotherapeutics, 2017
Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura   +2 more
doaj   +1 more source

CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies

open access: yesmAbs, 2022
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero   +5 more
doaj   +1 more source

On Pre-trained Language Models for Antibody [PDF]

open access: yesarXiv, 2023
Antibodies are vital proteins offering robust protection for the human body from pathogens. The development of general protein and antibody-specific pre-trained language models both facilitate antibody prediction tasks. However, there have been limited studies that comprehensively explore the representation capability of distinct pre-trained language ...
arxiv  

Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting

open access: yesAdvanced Materials, EarlyView.
CART cell therapy has proven effective for blood cancers but struggles with solid tumors due to diverse antigens and complex environments. Recent efforts focus on improving CAR design and validation platforms. Advances in protein engineering, machine learning, and organoid systems aim to enhance CAR‐T therapy against solid tumors.
Danqing Zhu   +4 more
wiley   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

open access: yes, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco   +2 more
core   +1 more source

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

open access: yesExperimental Hematology & Oncology, 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu   +6 more
doaj   +1 more source

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. [PDF]

open access: yesPLoS ONE, 2013
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors).
Zenjiro Sampei   +18 more
doaj   +1 more source

Bioorthogonal Reaction of o‐Quinone with Furan‐2(3H)‐One for Site‐Selective Tyrosine Conjugation and Construction of Bispecific Antibody Complexes

open access: yesAdvanced Science, EarlyView.
A site‐selective, efficient, and mild tyrosine conjugation via tyrosinase oxidation and nucleophilic addition, allowing for site‐selective functionalization of peptides, recombinant proteins, and IgGs. Site‐selective mono‐functionalization of IgGs at Y296 enables the construction of immunoliposomes.
Hongfei Chen   +13 more
wiley   +1 more source

CLEC5a-directed bispecific antibody for effective cellular phagocytosis

open access: yesmAbs, 2022
While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB).
Vivekananda Kedage   +11 more
doaj   +1 more source

Recent Advances in mRNA Delivery Systems for Cancer Therapy

open access: yesAdvanced Science, EarlyView.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy